nach oben

Current Fungal Infection Reports

Erschienen in:

28.05.2021 | Current Management of Fungal Infections (S Jacobs, Section Editor)

Investigational Agents for the Treatment of Resistant Yeasts and Molds

verfasst von: Garret T. Seiler, Luis Ostrosky-Zeichner

Erschienen in: Current Fungal Infection Reports | Ausgabe 3/2021

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

This review summarizes the investigational antifungals in clinical development with the potential to address rising drug resistance patterns. The relevant pharmacodynamics, spectrum of activity, preclinical studies, and latest clinical trial data are described.

Recent Findings

Agricultural and medicinal antifungal use has been selected for inherently drug-resistant fungi and acquired resistance mechanisms. The rates of fungal infections and immunocompromised populations continue to grow as few new antifungals have hit the market. Several agents with the potential to address the emergence of multidrug-resistant (MDR) molds and yeasts are in clinical development.

Summary

Evolved formulations of echinocandins, polyenes, and triazoles offer less toxicity, convenient dosing, and greater potency, potentially expanding these classes’ indications. Ibrexafungerp, olorofim, oteseconazole, and fosmanogepix possess novel mechanisms of actions with potent activity against MDR fungi. Successful clinical development is neither easy nor guaranteed; thus, perpetual efforts to discover new antifungals are needed.

Mourad A, Perfect J. Tolerability profile of the current antifungal armoury. Journal of Antimicrobial Chemotherapy. 2018;73:i26–32.CrossRef

Gintjee T, Donnelley M, Thompson G. Aspiring antifungals: review of current antifungal pipeline developments. Journal of Fungi. 2020;6:28.CrossRef

Vallabhaneni S, Mody R, Walker T, Chiller T. The global burden of fungal diseases. Infectious Disease Clinics of North America. 2016;30:1–11.CrossRef

Lum L, Lee A, Vu M, Strasser S, Davis R. Epidemiology and risk factors for invasive fungal disease in liver transplant recipients in a tertiary transplant center. Transpl Inf Dis. 2020:e13361.

Benedict K, Jackson BR, Chiller T, Beer KD. Estimation of direct healthcare costs of fungal diseases in the United States. Clin Inf Dis. 2019;68(11):1791–7. https://doi.org/10.1093/cid/ciy776.CrossRef

Verweij PE, Snelders E, Kema GH, Mellado E, Melchers WJ. Azole resistance in Aspergillus fumigatus: a side-effect of environmental fungicide use? The Lancet Infectious Diseases. 2009;9:789–95.CrossRef

Casadevall A, Kontoyiannis DP, Robert V. On the emergence of Candida auris: climate change, azoles, swamps and birds. mBio. 2019;10:e01397–19.PubMedPubMedCentral

Perlin DS, Rautemaa-Richardson R, Alastruey-Izquierdo A. The global problem of antifungal resistance: prevalence, mechanisms, and management. The Lancet Infectious Diseases. 2017;17:e383–92.CrossRef

Whaley SG, Berkow EL, Rybak JM, Nishimoto AT, Barker KS, Rogers PD. Azole antifungal resistance in Candida albicans and emerging non-albicans Candida species. Frontiers in Microbiology. 2017;7. https://doi.org/10.3389/fmicb.2016.02173.

10.

Adams E, Quinn M, Tsay S, Poirot E, Chaturvedi S, Southwick K, et al. Candida auris in healthcare facilities, New York, USA, 2013–2017. Emerging Infectious Diseases. 2018;24(10):1816–24. https://doi.org/10.3201/eid2410.180649.

11.

Forsberg K, Woodworth K, Walters M, Berkow EL, Jackson B, Chiller T, et al. Candida Auris : The recent emergence of a multidrug-resistant fungal pathogen. Medical Mycology. 2019;57(1):1–12. https://doi.org/10.1093/mmy/myy054.

12.

Walker TA, Lockhart SR, Beekmann SE, Polgreen PM, Santibanez S, Mody RK, et al. Recognition of azole-resistant aspergillosis by physicians specializing in infectious diseases, United States. Emerging Infectious Diseases. 2018;24.

13.

Hortschansky P, Misslinger M, Mörl J, Gsaller F, Bromley M, Brakhage A, et al. Structural basis of HapE P88L-linked antifungal triazole resistance in Aspergillus fumigatus. Life Science Alliance. 2020;3:e202000729. https://doi.org/10.26508/lsa.202000729.

14.

Ramirez-Garcia A, Pellon A, Rementeria A, Buldain I, Barreto-Bergter E, Rollin-Pinheiro R, et al. Scedosporium and Lomentospora: an updated overview of underrated opportunists. Medical Mycology. 2018;56(1):102–25.CrossRef

15.

Al-Hatmi AMS, de Hoog GS, Meis JF. Multiresistant Fusarium pathogens on plants and humans: solutions in the antifungal pipeline? Infect Drug Resist. 2019;12:3727–37. https://doi.org/10.2147/IDR.S180912.CrossRefPubMedPubMedCentral

16.

Schwarz P, Cornely OA, Dannaoui E. Antifungal combinations in Mucorales: a microbiological perspective. Mycoses. 2019;3:746–60.

17.

Tirado-Sánchez A, González GM, Bonifaz A. Endemic mycoses: epidemiology and diagnostic strategies. Expert Review of Anti-infective Therapy. 2020:1–13.

18.

CDC. Increase in reported coccidioidomycosis – United States, 1998-2011. MMWR. 2013;62(12):217–21.

19.

Parente-Rocha, Alves J, et al. Antifungal resistance, metabolic routes as drug targets, and new antifungal agents: an overview about endemic dimorphic fFungi. Mediators of Inflammation. 2017:1–16. https://doi.org/10.1155/2017/9870679.

20.

Davis MR, Donnelley MA, Thompson GR. Ibrexafungerp: a novel oral glucan synthase inhibitor. Medical Mycology. 2020;58(8):579–92.CrossRef

21.

Wring SA, Randolph R, Park S, et al. Preclinical pharmacokinetics and pharmacodynamic target of SCY-078, a first-in class orally active antifungal glucan synthesis inhibitor, in murine models of disseminated candidiasis. Antimicrob Agents Chemother. 2017;61:e02068–16.CrossRef

22.

Wring S, Murphy G, Atiee G, Corr C, Hyman M, Willett M, et al. Lack of impact by SCY-078, a first-in-class oral fungicidal glucan synthase inhibitor, on the pharmacokinetics of rosiglitazone, a substrate for CYP450 2C8, supports the low risk for clinically relevant metabolic drug-drug interactions. The Journal of Clinical Pharmacology. 2018;58:1305–13.

23.

Carruthers C, Barat S, Angulo D, Thomas P, Lewis E, Sobel R. Ibrexafungerp, a novel oral antifungal, demonstrates no reproductive or developmental harm in preclinical models. Obstetrics & Gynecology. 2019;133:114S.CrossRef

24.

• Nunnally NS, Etienne KA, Angulo D, et al. In vitro activity of ibrexafungerp, a novel glucan synthase inhibitor against Candida glabrata isolates with FKS mutations. Antimicrob Agents Chemother. 2019;63:11. https://doi.org/10.1128/AAC.01692-19Ibrexafungerp has activity against echinocandin-resistant C. glabrata.CrossRef

25.

Barat S, Borroto-Esoda K, Angulo D. SCY-078 Demonstrates significant tissue penetration in rats and mice following oral or IV administration. Open Forum Infectious Diseases. 2017;4:S471–1.

26.

• Zhu YYC, Barat SA, Borroto-Esoda K, Angulo D, Chaturvedi S, Chaturvedi V. Pan-resistant Candida auris isolates from the outbreak in New York are susceptible to ibrexafungerp (a glucan synthase inhibitor). Int J Antimicrob Agents. 2020;55(4):105922. https://doi.org/10.1016/j.ijantimicagIbrexafungerp maintained against pan-resistant C. auris isolated from human patients in New York.CrossRefPubMed

27.

•• Spec A, Pullman J, Thompson GR III, Powderly WG, Tobin EH, Vazquez J, et al. MSG-10: a phase 2 study of oral ibrexafungerp (SCY-078) following initial echinocandin therapy in non-neutropenic patients with invasive candidiasis. J of Antimicrob Chemother. 2019;74(10):3056–62 Ibrexafungerp showed efficacy in phase II study for invasive candidiasis.

28.

Cadet APA, Rebecca BA, Tufa MMD, Angulo DMD, Nyirjesy PMD. A Phase 2b, Dose-finding study evaluating oral ibrexafungerp vs fluconazole in vulvovaginal candidiasis (DOVE). Obstetrics & Gynecology. 2019;133:113S–4S. https://doi.org/10.1097/01.AOG.0000558840.33387.ee.CrossRef

29.

•• Trialsitenews.com (2020) Scynexis announces positive results from phase 3 VANISH-306 study of oral ibrexafungerp to treat vulvovaginal candidiasis. https://www.trialsitenews.com/scynexis-reports-positive-results-from-phase-3-vanish-306-trial-of-oral-ibrexafungerp-for-vaginal-yeast-infection. Accessed 11 Aug 2020. Oral ibrexafungerp showed efficacy in phase III study for VVC.

30.

•• Synexis.com (2019) SCYNEXIS announces positive interim results from Phase 3 open-label FURI study. https://www.scynexis.com/news-media/press-releases/detail/169/scynexis-announces-positive-interim-results-from-phase-3. Accessed 11 Aug 2020. Early data from phase III study show ibrexafungerp is efficacious in invasive fungal infections resistant or refractory to other antifungals.

31.

Krishnan BR, James KD, Polowy K, Bryant BJ, Vaidya A, Smith S, et al. CD101, a novel echinocandin with exceptional stability properties and enhanced aqueous solubility. J Antibiot. 2017;70:130–5.

32.

Tóth Z, Forgács L, Locke JB, Kardos G, Nagy F, Kovács R, et al. In vitro activity of rezafungin against common and rare Candida species and Saccharomyces cerevisiae. J Antimicrob Chemother. 2019;74:3505–10.

33.

Pfaller MA, Carvalhaes CG, Messer SA, Rhomberg PR, Castanheira M. Activity of a long-acting echinocandin rezafungin and comparator antifungal agents tested against contemporary invasive fungal isolates: (SENTRY Program, 2016 to 2018). Antimicrob Agents Chemother. 2020;64.

34.

Helleberg M, Jørgensen KM, Hare RK, Datcu R, Chowdhary A, Arendrup MC. Rezafungin In vitro activity against contemporary Nordic clinical Candida isolates and Candida auris determined by the EUCAST reference method. Antimicrob Agents Chemother. 2020;64.

35.

Hager CL, Larkin EL, Long LA, Ghannoum MA. Evaluation of the efficacy of rezafungin, a novel echinocandin, in the treatment of disseminated Candida auris infection using an immunocompromised mouse model. J Antimicrob Chemother. 2018;73:2085–8.CrossRef

36.

•• Thompson GR, Vazquez J, Soriano A, Skoutelis A, Ostrosky-Zeichner L, Mena K, et al. Rezafungin clinical safety and efficacy in patients with candidemia and/or invasive candidiasis in the randomized, double-blind, multicenter, phase 2 STRIVE study. Open Forum Infect Dis 2018;5. Rezafungin is effective and safe for patients with candidemia or invasive candidiasis.

37.

Cushion MT, Collins MS. Susceptibility of pneumocystis to echinocandins in suspension and biofilm cultures. Antimicrob Agents Chemother. 2011;55:4513–8.CrossRef

38.

• Cushion M, Ashbaugh A. Rezafungin prophylactic efficacy in a mouse model of pneumocystis pneumonia. Biol Blood Marrow Tr. 2019;25 Preclinical data suggesting a potential role of rezafungin for pneumocystis pneumonia prophylaxis, offering a potential single agent prophylaxis regimen for certain stem cell transplant recipients or other immunocompromised patients.

39.

Wiederhold NP, Locke JB, Daruwala P, Bartizal K. Rezafungin (CD101) demonstrates potent in vitro activity against Aspergillus, including azole-resistant Aspergillus fumigatus isolates and cryptic species. J Antimicrob Chemother. 2018;73:3063–7.CrossRef

40.

• Driscoll E, Clancy CJ, Nguyen M-H. 738. Potent in vitro activity of rezafungin (RZF) against Aspergillus clinical isolates recovered from lung transplant patients who have received ≥3 months of triazole prophylaxis. Open Forum Infect Dis. 2019;6 Rezafungin may have potential as salvage therapy for invasive mold infections breaking through triazole prophylaxis.

41.

Wiederhold NP, Najvar LK, Jaramillo R, Olivo M, Wickes BL, Catano G, et al. Extended-interval dosing of rezafungin against azole-resistant Aspergillus fumigatus. Antimicrob Agents Chemother. 2019;63.

42.

Warrilow AG, et al. The clinical candidate VT-1161 is a highly potent inhibitor of Candida albicans CYP51 but fails to bind the human enzyme. Antimicrob Agents Chemother. 2014;58(12):7121–7. https://doi.org/10.1128/aac.03707-14.CrossRefPubMedPubMedCentral

43.

Warrilow AG, Parker JE, Price CL, et al. The tetrazole VT-1161 is a potent inhibitor of Trichophyton rubrum through its inhibition of T. rubrum CYP51. Antimicrob Agents Chemother. 2017;61:e00333–17.CrossRef

44.

Schell WA, Jones AM, Garvey EP, et al. Fungal CYP51 inhibitors VT-1161 and VT-1129 exhibit strong in vitro activity against Candida glabrata and C. krusei isolates clinically resistant to azole and echinocandin antifungal compounds. Antimicrob Agents Chemother. 2017;61:e01817–6.PubMedPubMedCentral

45.

Gebremariam T, Wiederhold NP, Fothergill AW, Garvey EP, Hoekstra WJ, Schotzinger RJ, et al. VT-1161 protects immunosuppressed mice from Rhizopus arrhizus var. arrhizus infection. Antimicrob Agents Chemother. 2015;59:7815–7.

46.

Shubitz LF, Roy ME, Trinh HT, Hoekstra WJ, Schotzinger RJ, Garvey EP. Efficacy of the investigational antifungal VT-1161 in treating naturally occurring coccidioidomycosis in dogs. Antimicrob Agents Chemother. 2017;61:e00111–7. https://doi.org/10.1128/AAC.00111-17.CrossRefPubMedPubMedCentral

47.

• Elewski B, Brand S, Degenhardt T, Curelop S, Pollak R, Schotzinger R, et al. A phase II, randomized double-blinded, placebo controlled, dose-ranging study to evaluate the efficacy and safety of VT-1161 oral tablets in the treatment of patients with distal and lateral subungual onychomycosis of the toenail. Br J Dermatol. 2020. https://doi.org/10.1111/bjd.19224Phase II data showing efficacy for moderate to severe onychomycosis. Current antifungals for onychomycosis have low success rate, systemic toxicities and are primarily indicated for mild–moderate disease.

48.

• Brand SR, Degenhart TP, Person KL, et al. Oral VT-1161 is highly effective and safe in patients with recurrent vulvovaginal candidiasis - results of REVIVE, a multicenter phase 2b study. ASM Microbe. New Orleans: Viamet Pharmaceuticals. 2017; Phase II data supporting its use for recurrent vaginal candidiasis.

49.

Nishimoto AT, Wiederhold NP, Flowers SA, Zhang Q, Kelly SL, Morschhäuser J, et al. In vitro activities of the novel investigational tetrazoles vt-1161 and vt-1598 compared to the triazole antifungals against azole-resistant strains and clinical isolates of Candida albicans. Antimicrob Agents Chemother. 2019;63:1–11.

50.

Garvey EP, Hoekstra WJ, Schotzinger RJ, Sobel JD, Lilly EA, Fidel PL Jr. Efficacy of the clinical agent VT-1161 against fluconazole-sensitive and -resistant Candida albicans in a murine model of vaginal candidiasis. Antimicrob Agents Chemother. 2015;59:5567–73.CrossRef

51.

Miyazaki M, Horii T, Hata K, Watanabe NA, Nakamoto K, Tanaka K, et al. In vitro activity of E1210, a novel antifungal, against clinically important yeasts and molds. Antimicrob Agents Chemother. 2011;55:4652–8.

52.

Rivero-Menendez O, Cuenca-Estrella M, Alastruey-Izquierdo A. In vitro activity of APX001A against rare moulds using EUCAST and CLSI methodologies. J Antimicrob Chemother. 2019;74:1295–9.CrossRef

53.

Castanheira M, Duncanson FP, Diekema DJ, Guarro J, Jones RN, Pfaller MA. Activities of E1210 and comparator agents tested by CLSI and EUCAST broth microdilution methods against Fusarium and Scedosporium species identified using molecular methods. Antimicrob Agents Chemother. 2012;56:352–7.CrossRef

54.

Hager CL, Larkin EL, Long L, et al. In vitro and in vivo evaluation of the antifungal activity of APX001A/APX001 against Candida auris. Antimicrob Agents Chemother. 2018;62:e02319–7.CrossRef

55.

Jørgensen KM, Astvad KMT, Arendrup MC. In vitro activity of manogepix (APX001A) and comparators against contemporary molds: MEC comparison and preliminary experience with colorimetric MIC determination. Antimicrob Agents Chemother. 2020;64(8):e00730–20. https://doi.org/10.1128/AAC.00730-20.CrossRefPubMedPubMedCentral

56.

Arendrup MC, Jørgensen KM. Manogepix (APX001A) displays potent in vitro activity against human pathogenic yeast, but with an unexpected correlation to fluconazole MICs. Antimicrob Agents Chemother. 2020;64(7):e00429–0. https://doi.org/10.1128/AAC.00429-20.CrossRefPubMedPubMedCentral

57.

• Arendrup M, Chowdhary A, Jørgensen K, Meletiadis J. Manogepix (APX001A) in vitro activity against Candida auris. A head to head comparison of EUCAST and CLSI MICs. Antimicrob Agents Chemother. 2020. https://doi.org/10.1128/AAC.00656-20Fosmanogepix potently inhibits C. auris.

58.

• Wiederhold NP, Najvar LK, Shaw KJ, Jaramillo R, Patterson HP, Olivo M, et al. In vivo efficacy of delayed therapy with the novel inositol acyltransferase inhibitor fosmanogepix (APX001) in a murine model of Candida auris invasive candidiasis. Open Forum Infect Dis. 2019;6:S60–1. https://doi.org/10.1093/ofid/ofz359.131In vivo efficacy against Candida auris.

59.

• Gebremariam T, Alkhazraji S, Alqarihi A, Wiederhold NP, Shaw KJ, Patterson TF, et al. Fosmanogepix (APX001) is effective in the treatment of pulmonary murine mucormycosis due to Rhizopus arrhizus. Antimicrob Agents Chemother. 2020;64(6):e00178–20. https://doi.org/10.1128/AAC.00178-20In vivo data supporting fosmanogepix in treating mucormycosis.

60.

• Alkhazraji S, Gebremariam T, Alqarihi A, et al. Fosmanogepix (APX001) is effective in the treatment of immunocompromised mice infected with invasive pulmonary scedosporiosis or disseminated fusariosis. Antimicrob Agents Chemother. 2020;64(3):e01735–19. https://doi.org/10.1128/AAC.01735-19In vivo model demonstrating successful activity against often pan-resistant mold species.CrossRefPubMedPubMedCentral

61.

Kapoor M, Moloney M, Soltow QA, Pillar CM, Shaw KJ. Evaluation of resistance development to the Gwt1 inhibitor manogepix (APX001A) in Candida species. Antimicrob Agents Chemother. 2019;64:1. https://doi.org/10.1128/aac.01387-19.CrossRef

62.

•• Amplyx.com. (2020) Amplyx announces positive top-line data in phase 2 clinical trial of novel antifungal fosmanogepix. amplyx.com/amplyx-announces-positive-top-line-data-in-phase-2-clinical-trial-of-novel-antifungal-fosmanogepix/. Accessed 4 Aug 2020. Phase 2 clinical trial data recently released showing fosmanogepix’s efficacy in treating invasive candidiasis caused by antifungal-resistant Candida species. All isolates were susceptible to the drug.

63.

Oliver JD, Sibley GE, Beckmann N, et al. F901318 represents a novel class of antifungal drug that inhibits dihydroorotate dehydrogenase. Proc Natl Acad Sci USA. 2016;113:12809–14.CrossRef

64.

Wiederhold N. Review of the novel investigational antifungal olorofim. J Fungi. 2020;6:122. https://doi.org/10.3390/jof6030122.CrossRef

65.

• Rivero-Menendez O, Cuenca-Estrella M, Alastruey-Izquierdo A. In vitro activity of olorofim (F901318) against clinical isolates of cryptic species of Aspergillus by EUCAST and CLSI methodologies. J Antimicrob Chemother. 2019;74:1586–90 In vitro activity against cryptic (often MDR) Aspergillus species.CrossRef

66.

• Kirchhoff L, Dittmer S, Weisner A, Buer J, Rath P, Steinmann J. In vitro activity of olorofim (F901318) against fungi of the genus, Scedosporium and Rasamsonia as well as against Lomentospora prolificans, Exophiala dermatitidis and azole-resistant Aspergillus fumigatus. Int J Antimicrob. 2020:0924–8579. https://doi.org/10.1016/j.ijantimicag.2020.106105Olorofim has in vitro activity against MDR molds without reliable treatments available.

67.

Wiederhold NP, Patterson HP, Birch M, Law D. Evaluation of the in vitro activity of olorofim against Fusarium species. In Proceedings of the 9th Trends in Medical Mycology, Nice, France, 11–19 October 2019.

68.

• Kirchhoff L, Dittmer S, Weisner A, Buer J, Rath P, and Steinmann J. Antibiofilm activity of antifungal drugs, including the novel drug olorofim, against Lomentospora prolificans. J Antimicrob Chemother 2020; https://doi.org/10.1093/jac/dkaa157. Olorofim has in vitro activity against Lomentospora spp. and penetrates biofilms. Currently antifungals have poor biofilm penetration. Biofilms significantly contribute to drug resistance.

69.

Hope W, McEntee L, Livermore J, Whalley S, Johnson A, Farrington N, et al. Pharmacodynamics of the orotomides against Aspergillus fumigatus: new opportunities for treatment of multidrug-resistant fungal disease. mBio. 2017;8:e01157–17.

70.

Negri C, Johnson A, McEntee L, Box H, Whalley S, Schwartz J, et al. Pharmacodynamics of the novel antifungal agent F901318 for acute sinopulmonary aspergillosis caused by Aspergillus flavus. J Infect Dis. 2017;217:1118–27.

71.

Seyedmousavi S, Chang YC, Law D, Birch M, Rex JH, Kwon-Chung KJ. Efficacy of olorofim (F901318) against Aspergillus fumigatus, A. nidulans, and A. tanneri in murine models of profound neutropenia and chronic granulomatous disease. Antimicrob Agents Chemother. 2019;63.

72.

Fothergill AW, Wiederhold NP, Sibley G, Kennedy A, Oliver J, Birch M, et al. Spectrum of activity of F901318, the first agent from the newly discovered orotomide class of antifungals. ICAAC/ICC. 2015.

73.

Wiederhold N, Najvar L, Jaramillo R, Olivo M, Birch M, Law D, et al. The orotomide olorofim is efficacious in an experimental model of central nervous system coccidioidomycosis. Antimicrob Agents Chemother. 2018;62:9. https://doi.org/10.1128/AAC.00999-18.

74.

Aigner M, Lass-Flörl C. Encochelated amphotericin B: is the oral availability of amphotericin B finally reached? J Fungi. 2020;6(2):66. https://doi.org/10.3390/jof6020066.CrossRef

75.

Delmas G, Park S, Chen ZW, Tan F, Kashiwazaki R, Zarif L, et al. Efficacy of orally delivered cochleates containing amphotericin B in a murine model of aspergillosis. Antimicrob Agents Chemother. 2002;46:2704–7.

76.

Mannino R, Perlin D. Oral dosing of encochleated amphotericin B (CAmB): rapid drug targeting to infected tissues in mice with invasive candidiasis. Scientific Presentations & Publications Matinas Biopharma 2015. Available online: https://www.matinasbiopharma.com/media/scientific-presentations-publications. Accessed 12 Aug 2020.

77.

Lu R, Hollingsworth C, Qiu J, Wang A, Hughes E, Xin X, et al. Efficacy of oral encochleated amphotericin B in a mouse model of cryptococcal meningoencephalitis. mBio. 2019;10:3. https://doi.org/10.1128/mBio.00724-19.

78.

• Skipper C, Atukunda M, Stadelman A, Engen N, Bangdiwala A, Hullsiek KH, et al. Safety and tolerability of a novel oral formulation of amphotericin B: phase I EnACT trial. Antimicrob Agents Chemother. 2020. https://doi.org/10.1128/AAC.00838-20Recent phase I data showing oral encochleated amphotericin B is easily tolerated with better safety compared to parenteral amphotericin B.

79.

Kibathi L, Kumar P, Lionakis M, Urban A, Ferre E, McManus M, et al. 1413. A phase IIa efficacy, safety, tolerability and pharmacokinetic (PK) study of encochleated amphotericin B in patients with mucocutaneous (esophageal, oropharyngeal, vulvovaginal) candidiasis who are refractory or intolerant to standard non-intravenous therapies. Open Forum Infect Dis. 2018;5(1):S435–5. https://doi.org/10.1093/ofid/ofy210.1244.

80.

U.S. National Library of Medicine. ClinivalTrials.gov. NCT02971007. Safety and efficacy of oral encochleated amphotericin B (CAMB/MAT2203) in the treatment of vulvovaginal candidiasis (VVC). Available online: https://clinicaltrials.gov/ct2/show/nct02971007. Accessed 12 Aug 2020.

81.

Colley T, Alanio A, Kelly SL, Sehra G, Kizawa Y, Warrilow AGS, et al. In vitro and in vivo antifungal profile of a novel and long-acting inhaled azole, PC945, on aspergillus fumigatus infection. Antimicrob Agents Chemother. 2017;61(5):e02280–16. https://doi.org/10.1128/aac.02280-16.

82.

Rudramurth S, et al. In vitro antifungal activity of a novel topical triazole PC945 against emerging yeast Candida auris. J Antimicrob Chemother. 2019;74(10):2943–9. https://doi.org/10.1093/jac/dkz280.CrossRef

83.

Colley T, Sehra G, Daly L, et al. Antifungal synergy of a topical triazole, PC945, with a systemic triazole against respiratory Aspergillus fumigatus infection. Sci Rep. 2019;9:9482. https://doi.org/10.1038/s41598-019-45890-w.CrossRefPubMedPubMedCentral

84.

Pulmocide.com (2020). PC945 is a novel, potent, fungicidal anti-Aspergillus compound. Available at: http://pulmocide.com/product/pc945/. Accessed on Aug 19 2020.

85.

Yamashita K, Miyazaki T, Fukuda Y, et al. The novel arylamidine T-2307 selectively disrupts yeast mitochondrial function by inhibiting respiratory chain complexes. Antimicrob Agents Chemother. 2019;63:e00374–19.PubMedPubMedCentral

86.

Mitsuyama J, Nomura N, Hashimoto K, Yamada E, Nishikawa H, Kaeriyama M, et al. In vitro and in vivo antifungal activities of T-2307, a novel arylamidine. Antimicrob Agents Chemother. 2008;52:1318–24.

87.

Nishikawa H, Fukuda Y, Mitsuyama J, Tashiro M, Tanaka A, Takazono T, et al. In vitro and in vivo antifungal activities of T-2307, a novel arylamidine, against Cryptococcus gattii: an emerging fungal pathogen. J Antimicrob Chemother. 2017;72:1709–13.

88.

Wiederhold NP, Najvar LK, Fothergill AW, Bocanegra R, Olivo M, McCarthy DI, et al. The novel arylamidine T-2307 demonstrates in vitro and in vivo activity against echinocandin-resistant Candida glabrata. J Antimicrob Chemother. 2016;71:692–5.

89.

Wiederhold NP, Najvar LK, Fothergill AW, et al. The novel arylamidine T-2307 demonstrates in vitro and in vivo activity against Candida auris. J Antimicrob Chemother. 2019;64(3):e02198–19. https://doi.org/10.1128/AAC.02198-19.CrossRef

90.

Abe M, Nakamura S, Kinjo Y. Efficacy of T-2307, a novel arylamidine, against ocular complications of disseminated candidiasis in mice. J Antimicrob Chemother. 2019;74:1327–32.CrossRef

91.

• Appilitherapeutics.com (2020). A novel, broad-spectrum, clinical stage antifungal to address severe and difficult-to-treat invasive fungal infections. Available online: https://www.appilitherapeutics.com/ati-2307. Accessed 10 Aug 2020. This agent was previously T-2307 until it lost funding for further development. Now Appili Therapeutics has recently acquired it to continue development.

92.

Lockhart SR, Fothergill AW, Iqbal N, Bolden CB, Grossman NT, Garvey EP, et al. The investigational fungal Cyp51 inhibitor VT-1129 demonstrates potent in vitro activity against Cryptococcus neoformans and Cryptococcus gattii. Antimicrob Agents Chemother. 2016;60:2528–31.

93.

Nielsen K, Vedula P, Smith KD, Meya DB, Garvey EP, Hoekstra WJ, et al. Activity of VT-1129 against Cryptococcus neoformans clinical isolates with high fluconazole MICs. Med Mycol J. 2017;55(4):453–6. https://doi.org/10.1093/mmy/myw089.

94.

Wiederhold NP, Najvar LK, Garvey EP, Brand SR, Xu X, Ottinger EA, et al. The fungal Cyp51 inhibitor VT-1129 is efficacious in an experimental model of cryptococcal meningitis. Antimicrob Agents Chemother. 2018;62.

95.

Desai JV, et al. VT-1129 and VT-1161 have in vitro activity against Candida isolates from patients with chronic mucocutaneous candidiasis. Open Forum Infect Dis. 2017;3(1):1635. https://doi.org/10.1093/ofid/ofw172.1335.CrossRef

96.

Wiederhold NP, Patterson HP, Tran BH, Yates CM, Schotzinger RJ, Garvey EP. Fungal-specific Cyp51 inhibitor VT-1598 demonstrates in vitro activity against Candida and Cryptococcus species, endemic fungi, including Coccidioides species, Aspergillus species and Rhizopus arrhizus. J Antimicrob Chemother. 2018;73(2):404–8. https://doi.org/10.1093/jac/dkx410.CrossRefPubMed

97.

Nishimoto A, Whaley S, Wiederhold N, Zhang Q, Yates C, Hoekstra W, et al. Impact of the major Candida glabrata triazole resistance determinants on the activity of the novel investigational tetrazoles VT-1598 and VT-1161. Antimicrob Agents Chemother. 2019;63.

98.

Wiederhold NP, Lockhart SR, Najvar LK, et al. The fungal Cyp51-specific inhibitor VT-1598 demonstrates in vitro and in vivo activity against Candida auris. Antimicrob Agents Chemother. 2019;63:e02233–18.PubMedPubMedCentral

99.

Garvey EP, Sharp AD, Warn PA, Yates CM, Schotzinger RJ. The novel fungal CYP51 inhibitor VT-1598 is efficacious alone and in combination with liposomal amphotericin B in a murine model of cryptococcal meningitis. J Antimicrob Chemother. 2018;73(10):2815–22. https://doi.org/10.1093/jac/dky242.CrossRefPubMed

100.

Wiederhold NP, Shubitz LF, Najvar LK, et al. The novel fungal Cyp51 inhibitor VT-1598 is efficacious in experimental models of central nervous system coccidioidomycosis caused by Coccidioides posadasii and Coccidioides immitis. Antimicrob Agents Chemother. 2018;62:e02258–17.PubMedPubMedCentral

101.

Hector RF, Zimmer BL, Pappagianis D. Evaluation of nikkomycins X and Z in murine models of coccidioidomycosis, histoplasmosis, and blastomycosis. Antimicrob Agents Chemother. 1990;34:587–93.CrossRef

102.

Shubitz LF, Roy ME, Nix DE, Galgiani JN. Efficacy of nikkomycin Z for respiratory coccidioidomycosis in naturally infected dogs. Med Mycol. 2013;51:747–54.CrossRef

103.

Cheung Y-Y, Hui M. Effects of echinocandins in combination with nikkomycin Z against invasive Candida albicans bloodstream isolates and the fks mutants. Antimicrob Agents Chemother. 2017;61:e00619–7.CrossRef

104.

Nix DE, Swezey RR, Hector R, Galgiani JN. Pharmacokinetics of nikkomycin Z after single rising oral doses. Antimicrob Agents Chemother. 2009;53:2517–21.CrossRef

105.

Pfaller MA, Messer SA, Georgopapadakou N, Martell LA, Besterman JM, Diekema DJ. Activity of MGCD290, a Hos2 histone deacetylase inhibitor, in combination with azole antifungals against opportunistic fungal pathogens. J Clin Microbiol. 2009;47:3797–804.CrossRef

106.

Pfaller MA, Rhomberg PR, Messer SA, Castanheira M. In vitro activity of a Hos2 deacetylase inhibitor, MGCD290, in combination with echinocandins against echinocandin-resistant Candida species. Diagn Microbiol Infect Dis. 2015;81(4):259–63. https://doi.org/10.1016/j.diagmicrobio.2014.11.008.CrossRefPubMed

Titel: Investigational Agents for the Treatment of Resistant Yeasts and Molds
verfasst von: Garret T. Seiler
Luis Ostrosky-Zeichner
Publikationsdatum: 28.05.2021
Verlag: Springer US
Erschienen in: Current Fungal Infection Reports / Ausgabe 3/2021
Print ISSN: 1936-3761
Elektronische ISSN: 1936-377X
DOI: https://doi.org/10.1007/s12281-021-00419-5

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

16.04.2024 | Spondylitis ankylosans | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Investigational Agents for the Treatment of Resistant Yeasts and Molds

Abstract

Purpose of Review

Recent Findings

Summary

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Vorsicht mit hohen NSAR-Dosen bei ankylosierender Spondylitis!

Sind Betablocker auch für ältere herzschwache Personen nützlich?

Kein Abstrich bei chronischen Wunden ohne Entzündungszeichen!

Manche Gestagene können das Risiko für Meningeome erhöhen

Update Innere Medizin

Springer Medizin

Abstract

Purpose of Review

Recent Findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2021

Scedosporium and Lomentospora infections in lung transplant recipients

Candida auris: Diagnostic Challenges and Emerging Opportunities for the Clinical Microbiology Laboratory

Cytopathology of Fungal Infections

Molecular Diagnosis of Yeast Infections

Emergence of Triazole Resistance in Aspergillus spp. in Latin America

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Vorsicht mit hohen NSAR-Dosen bei ankylosierender Spondylitis!

Sind Betablocker auch für ältere herzschwache Personen nützlich?

Kein Abstrich bei chronischen Wunden ohne Entzündungszeichen!

Manche Gestagene können das Risiko für Meningeome erhöhen

Update Innere Medizin